SCHEMBL6736115

SCHEMBL6736115

CCN(CC)C(C)N1C(=O)c2c(c3c4ccccc4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4ccccc4c23)C1=O

nearest known ligand 0.78

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PRKCA P17252 6/20 0.78
▸ TOP1 P11387 12/20 0.54
▸ PRKCQ Q04759 2/20 0.51
▸ DYRK1A Q13627 1/20 0.51
▸ PAX8 Q06710 1/20 0.51
▸ PRKD3 O94806 1/20 0.47
▸ PRKCG P05129 1/20 0.47
▸ PRKCB P05771 1/20 0.47
▸ PRKCH P24723 1/20 0.47
▸ PRKCI P41743 1/20 0.47
▸ PRKCE Q02156 1/20 0.47
▸ PRKCZ Q05513 1/20 0.47
▸ PRKCD Q05655 1/20 0.47
▸ PRKD1 Q15139 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6735508 0.88 PRKCA (0.60) PRKCATOP1PRKCQDYRK1APAX8
SCHEMBL6730339 0.88 PRKCA (0.88) PRKCATOP1PRKCQDYRK1APAX8
SCHEMBL6736119 0.86 PRKCA (0.77) PRKCATOP1PRKCQDYRK1APAX8
SCHEMBL6736494 0.86 PRKCA (0.85) PRKCATOP1PRKCQDYRK1APAX8
SCHEMBL6738330 0.86 PRKCA (0.84) PRKCATOP1PRKCQDYRK1APAX8
SCHEMBL6738264 0.85 PRKCA (0.83) PRKCATOP1PRKCQDYRK1APAX8
SCHEMBL6740483 0.79 PRKCA (0.72) PRKCATOP1PRKCQDYRK1APAX8
SCHEMBL6734350 0.76 PRKCA (0.66) PRKCATOP1PRKCQDYRK1APAX8
SCHEMBL5982059 0.75 PRKCA (0.80) PRKCATOP1
SCHEMBL6735510 0.75 PRKCA (0.59) PRKCATOP1PRKCQDYRK1APAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040242508-A1 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same LES LABORATOIRES SERVIER (FR) 2004-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242508-A1 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same RDX, HAX1, HRH1 PRKCA 3832/4885TOP1 242/4885PRKCQ 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback